Print ISSN: 2581-5725
Online ISSN: 2456-9267
CODEN : IACHCL
IP Archives of Cytology and Histopathology Research (ACHR) open access, peer-reviewed quarterly journal publishing since 2016 and is published under the Khyati Education and Research Foundation (KERF), is registered as a non-profit society (under the society registration act, 1860), Government of India with the vision of various accredited vocational courses in healthcare, education, paramedical, yoga, publication, teaching and research activity, with the aim of faster and better dissemination of knowledge, we will be publishing the article more...Case Report
Author Details :
Volume : 8, Issue : 4, Year : 2023
Article Page : 285-287
https://doi.org/10.18231/j.achr.2023.065
Abstract
Adenoid cystic carcinoma of breast is rare, accounting for less than 4% of all breast malignancy. We are presenting a case of 57 Year old Hindu female patient who presented with chief complaint of right breast swelling since 5 years associated with pain.USG report showed well defined isoechoic to hypoechoic lesion without internal vascularity, with a possibility of fibroadenoma of right breast. FNAC of the lesion was also suggestive of fibroadenoma. The wide local excision was done, tissue specimen was sent for histopathological examination which was diagnosed as adenoid cystic carcinoma of right breast after immunohistochemical characterization. Immunochemistry markers show ER, PR HER 2: negative, P -63: Positive for myoepithelial cells, Ki 67: <10>
Keywords: Adenoid cystic carcinoma, Myoepithelial cells, Ductal cells, Immunohistochemistry
How to cite : Damor D, Shah R, Patel F, Jhala K, Goyal A D, Adenoid cystic carcinoma of breast: A rare case report. IP Arch Cytol Histopathol Res 2023;8(4):285-287
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.